

Danial E Baker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4600281/publications.pdf>

Version: 2024-02-01

313
papers

1,256
citations

516215

16
h-index

525886

27
g-index

358
all docs

358
docs citations

358
times ranked

1643
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivir. Hospital Pharmacy, 2023, 58, 420-430.	0.4	3
2	Lefamulin. Hospital Pharmacy, 2022, 57, 704-711.	0.4	2
3	Ferric Derisomaltose. Hospital Pharmacy, 2020, , 001857872094676.	0.4	0
4	Crizanlizumab. Hospital Pharmacy, 2020, , 001857872092537.	0.4	1
5	Cetirizine Hydrochloride Injection. Hospital Pharmacy, 2020, , 001857872091038.	0.4	1
6	Formulary Drug Reviews: Brexanolone Injection. Hospital Pharmacy, 2019, , 001857871986768.	0.4	0
7	Formulary Drug Review: Sufentanil Sublingual. Hospital Pharmacy, 2019, 54, 222-228.	0.4	1
8	Baloxavir Marboxil. Hospital Pharmacy, 2019, 54, 165-169.	0.4	6
9	Omadacycline. Hospital Pharmacy, 2019, 54, 80-87.	0.4	3
10	Nasal Glucagon. Hospital Pharmacy, 2019, , 001857871988891.	0.4	0
11	Risankizumab. Hospital Pharmacy, 2019, , 001857871987387.	0.4	1
12	Sodium Zirconium Cyclosilicate. Hospital Pharmacy, 2019, 54, 12-19.	0.4	5
13	Zoster Vaccine Recombinant, Adjuvanted. Hospital Pharmacy, 2018, 53, 136-141.	0.4	3
14	Formulary Drug Reviews: Glecaprevir/Pibrentasvir. Hospital Pharmacy, 2018, 53, 75-84.	0.4	1
15	Formulary Drug Review: Betrixaban. Hospital Pharmacy, 2018, 53, 29-37.	0.4	6
16	Erenumab-aooe. Hospital Pharmacy, 2018, 53, 363-368.	0.4	4
17	Angiotensin II. Hospital Pharmacy, 2018, 53, 230-233.	0.4	0
18	Coagulation Factor Xa (Recombinant), Inactivated-zhzo (Andexanet Alfa). Hospital Pharmacy, 2018, 53, 286-291.	0.4	8

#	ARTICLE	IF	CITATIONS
19	Insulin Degludec/Liraglutide. Hospital Pharmacy, 2017, 52, 374-380.	0.4	1
20	Formulary Drug Review: Etelcalcetide. Hospital Pharmacy, 2017, 52, 669-674.	0.4	2
21	Lixisenatide. Hospital Pharmacy, 2017, 52, 65-80.	0.4	3
22	Bezlotoxumab. Hospital Pharmacy, 2017, 52, 229-233.	0.4	2
23	Formulary Drug Review: Naldemedine. Hospital Pharmacy, 2017, 52, 464-468.	0.4	2
24	Formulary Drug Review: Safinamide. Hospital Pharmacy, 2017, 52, 532-543.	0.4	2
25	Formulary Drug Review: Ocrelizumab. Hospital Pharmacy, 2017, 52, 599-606.	0.4	0
26	Formulary Drug Review: Edaravone. Hospital Pharmacy, 2017, 52, 732-736.	0.4	6
27	For Sale: FDA Priority Review Vouchers. Hospital Pharmacy, 2017, 52, 324-325.	0.4	0
28	Formulary Drug Reviews: Plecanatide. Hospital Pharmacy, 2017, 52, 400-405.	0.4	1
29	Irinotecan Liposome Injection. Hospital Pharmacy, 2017, 52, 144-150.	0.4	8
30	High Drug Prices: So who is to Blame?. Hospital Pharmacy, 2017, 52, 5-6.	0.4	3
31	Eteplirsen. Hospital Pharmacy, 2017, 52, 302-305.	0.4	9
32	Uridine Triacetate. Hospital Pharmacy, 2016, 51, 484-488.	0.4	13
33	Idarucizumab. Hospital Pharmacy, 2016, 51, 256-262.	0.4	0
34	Zika Virus and the Media. Hospital Pharmacy, 2016, 51, 275-276.	0.4	5
35	Surrogate Markers and Drug Approvals. Hospital Pharmacy, 2016, 51, 611-614.	0.4	2
36	Daclizumab. Hospital Pharmacy, 2016, 51, 928-939.	0.4	4

#	ARTICLE	IF	CITATIONS
37	Rolapitant. Hospital Pharmacy, 2016, 51, 165-175.	0.4	0
38	Mepolizumab. Hospital Pharmacy, 2016, 51, 405-414.	0.4	3
39	Elbasvir/Grazoprevir. Hospital Pharmacy, 2016, 51, 665-686.	0.4	6
40	Defibrotide. Hospital Pharmacy, 2016, 51, 847-854.	0.4	12
41	Fentanyl Iontophoretic Transdermal System. Hospital Pharmacy, 2016, 51, 71-82.	0.4	0
42	Patiomer. Hospital Pharmacy, 2016, 51, 328-336.	0.4	3
43	Sugammadex. Hospital Pharmacy, 2016, 51, 585-596.	0.4	13
44	Ivradine. Hospital Pharmacy, 2015, 50, 806-817.	0.4	0
45	Sacubitril/Valsartan. Hospital Pharmacy, 2015, 50, 1025-1036.	0.4	7
46	US Food and Drug Administration Web Site: A Primer for Pharmacists. Hospital Pharmacy, 2015, 50, 985-993.	0.4	0
47	Ceftolozane/Tazobactam. Hospital Pharmacy, 2015, 50, 526-533.	0.4	2
48	Volunteerism and Professional Development. Hospital Pharmacy, 2015, 50, 655-656.	0.4	0
49	Pharmacy and the "Zombie Apocalypse". Hospital Pharmacy, 2015, 50, 957-958.	0.4	2
50	Cangrelor. Hospital Pharmacy, 2015, 50, 922-929.	0.4	24
51	Secukinumab. Hospital Pharmacy, 2015, 50, 714-727.	0.4	6
52	What is your Institution's Position Going to be on Biosimilars?. Hospital Pharmacy, 2015, 50, 435-436.	0.4	0
53	Edoxaban. Hospital Pharmacy, 2015, 50, 619-634.	0.4	5
54	Naloxegol. Annals of Pharmacotherapy, 2015, 49, 360-365.	0.9	13

#	ARTICLE	IF	CITATIONS
55	Ferric Citrate. Hospital Pharmacy, 2015, 50, 139-151.	0.4	4
56	Ledipasvir/Sofosbuvir. Hospital Pharmacy, 2015, 50, 224-234.	0.4	5
57	Netupitant/Palonosetron. Hospital Pharmacy, 2015, 50, 310-328.	0.4	3
58	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir. Hospital Pharmacy, 2015, 50, 396-415.	0.4	4
59	Medication Counterfeiting. Hospital Pharmacy, 2014, 49, 683-684.	0.4	2
60	Legalization of Recreational and Medical Marijuana: What We Don't Know. Hospital Pharmacy, 2014, 49, 319-320.	0.4	0
61	Dalbavancin. Hospital Pharmacy, 2014, 49, 851-861.	0.4	6
62	Ferric Carboxymaltose. Hospital Pharmacy, 2014, 49, 52-69.	0.4	10
63	Tedizolid Phosphate. Hospital Pharmacy, 2014, 49, 961-971.	0.4	4
64	Dapagliflozin. Hospital Pharmacy, 2014, 49, 647-662.	0.4	3
65	Sofosbuvir. Hospital Pharmacy, 2014, 49, 466-478.	0.4	7
66	Simeprevir Capsules. Hospital Pharmacy, 2014, 49, 376-389.	0.4	0
67	Umeclidinium Bromide and Vilanterol Trifenatate Inhalation Powder. Hospital Pharmacy, 2014, 49, 554-562.	0.4	4
68	Has the Time Come for "Medication Tourism"? Hospital Pharmacy, 2014, 49, 999-1000.	0.4	5
69	Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Hospital Pharmacy, 2014, 49, 73-96.	0.4	1
70	Dolutegravir. Hospital Pharmacy, 2014, 49, 184-195.	0.4	2
71	Apremilast. Hospital Pharmacy, 2014, 49, 752-762.	0.4	14
72	Conjugated Estrogens and Bazedoxifene. Hospital Pharmacy, 2014, 49, 273-283.	0.4	9

#	ARTICLE	IF	CITATIONS
73	Oritavancin diphosphate. Hospital Pharmacy, 2014, 49, 1049-60.	0.4	2
74	Alogliptin. Hospital Pharmacy, 2013, 48, 580-592.	0.4	5
75	Canagliflozin. Hospital Pharmacy, 2013, 48, 855-867.	0.4	5
76	Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Tablets. Hospital Pharmacy, 2013, 48, 48-56.	0.4	8
77	Prothrombin Complex Concentrate. Hospital Pharmacy, 2013, 48, 951-957.	0.4	11
78	Doxylamine Succinate/Pyridoxine Hydrochloride. Hospital Pharmacy, 2013, 48, 762-766.	0.4	4
79	Nonprescription Drug Safe Use Regulatory Expansion. Hospital Pharmacy, 2013, 48, 448-450.	0.4	1
80	Teriflunomide. Hospital Pharmacy, 2013, 48, 231-240.	0.4	12
81	Tofacitinib. Hospital Pharmacy, 2013, 48, 413-424.	0.4	29
82	Apixaban. Hospital Pharmacy, 2013, 48, 494-511.	0.4	10
83	Breakthrough Drug Approval Process and Postmarketing ADR Reporting. Hospital Pharmacy, 2013, 48, 796-798.	0.4	0
84	Dimethyl Fumarate. Hospital Pharmacy, 2013, 48, 668-679.	0.4	17
85	Linacotide. Hospital Pharmacy, 2013, 48, 143-152.	0.4	3
86	Perampanel. Hospital Pharmacy, 2013, 48, 321-331.	0.4	3
87	Exenatide Extended-Release Injection. Hospital Pharmacy, 2012, 47, 633-644.	0.4	0
88	Glucarpidase. Hospital Pharmacy, 2012, 47, 463-470.	0.4	1
89	Biogeneric versus Biosimilar Products. Hospital Pharmacy, 2012, 47, 822-824.	0.4	0
90	Ivermectin 0.5% Topical Lotion. Hospital Pharmacy, 2012, 47, 721-724.	0.4	0

#	ARTICLE	IF	CITATIONS
91	Rivaroxaban in Nonvalvular Atrial Fibrillation. Hospital Pharmacy, 2012, 47, 293-304.	0.4	1
92	Deferiprone. Hospital Pharmacy, 2012, 47, 129-136.	0.4	2
93	Phentermine/Topiramate Extended Release. Hospital Pharmacy, 2012, 47, 950-958.	0.4	0
94	Aflibercept. Hospital Pharmacy, 2012, 47, 375-381.	0.4	0
95	Lorcaserin Hydrochloride. Hospital Pharmacy, 2012, 47, 871-879.	0.4	0
96	Indacaterol. Hospital Pharmacy, 2012, 47, 219-236.	0.4	0
97	Should the Term "Statistical Significance" and P Values Go Away in Pharmacy Publications?. Hospital Pharmacy, 2012, 47, 420-420.	0.4	0
98	Ivacaftor. Hospital Pharmacy, 2012, 47, 544-549.	0.4	0
99	Lucinactant. Hospital Pharmacy, 2012, 47, 788-793.	0.4	0
100	Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Hospital Pharmacy, 2012, 47, 798-802.	0.4	0
101	Spinosad 0.9% Topical Suspension. Hospital Pharmacy, 2011, 46, 436-440.	0.4	1
102	Acetaminophen Intravenous. Hospital Pharmacy, 2011, 46, 273-285.	0.4	2
103	Pegloticase. Hospital Pharmacy, 2011, 46, 41-47.	0.4	0
104	Dabigatran. Hospital Pharmacy, 2011, 46, 196-207.	0.4	1
105	Ceftaroline Fosamil. Hospital Pharmacy, 2011, 46, 349-358.	0.4	0
106	New Drugs Approved by the FDA: New Dosage Forms and Indications Approved by the FDA: Agents Pending FDA Approval: Supplemental Applications Filed by Manufacturer: Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety. Hospital Pharmacy, 2011, 46, 445-449.	0.4	0
107	Linagliptin. Hospital Pharmacy, 2011, 46, 685-699.	0.4	0
108	Roflumilast. Hospital Pharmacy, 2011, 46, 597-606.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Boceprevir and Telaprevir. Hospital Pharmacy, 2011, 46, 779-796.	0.4	0
110	New Drugs Approved by the FDA/New Dosage Forms and Indications Approved by the FDA/Agents Pending FDA Approval/Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety. Hospital Pharmacy, 2010, 45, 404-417.	0.4	0
111	Buprenorphine Transdermal System. Hospital Pharmacy, 2010, 45, 863-870.	0.4	0
112	New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; New Drug/Biologics License Applications Filed by Manufacturer; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety. Hospital Pharmacy, 2010, 45, 496-502.	0.4	0
113	Rifaximin. Hospital Pharmacy, 2010, 45, 712-717.	0.4	1
114	New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes or "Dear Health Professional" Letters Related to Safety. Hospital Pharmacy, 2010, 45, 567-571.	0.4	0
115	The Last Step of the Residency Projects: Publication. Hospital Pharmacy, 2010, 45, 672-673.	0.4	2
116	Aztreonam Lysine Inhalation Solution. Hospital Pharmacy, 2010, 45, 634-641.	0.4	0
117	Glycopyrrolate Oral Solution. Hospital Pharmacy, 2010, 45, 939-943.	0.4	1
118	Telavancin. Hospital Pharmacy, 2010, 45, 142-149.	0.4	0
119	New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; New Drug or Biologics License Applications Filed by Manufacturer; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes or "Dear Health Care Professional" Letters Related to Safety. Hospital Pharmacy, 2009, 44, 340-344.	0.4	1
120	Awareness of Risk Evaluation and Mitigation Strategy Program for New Drugs. Hospital Pharmacy, 2009, 44, 208-209.	0.4	2
121	Medication Alert Fatigue: The Potential for Compromised Patient Safety. Hospital Pharmacy, 2009, 44, 460-461.	0.4	11
122	Acetaminophen: Is it Time for a Change in Utilization to Decrease the Risk of Hepatotoxicity?. Hospital Pharmacy, 2009, 44, 843-845.	0.4	3
123	New Drugs Approved by the FDA; New Dosage Forms and Indications Approved by the FDA; Agents Pending FDA Approval; New Drug/Biologics License Applications Filed by Manufacturer; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes or "Dear Health Care Professional" Letters Related to Safety. Hospital Pharmacy, 2009, 44, 619-622.	0.4	0
124	Tolvaptan. Hospital Pharmacy, 2009, 44, 998-1009.	0.4	0
125	Milnacipran. Hospital Pharmacy, 2009, 44, 604-618.	0.4	3
126	Dronedarone. Hospital Pharmacy, 2009, 44, 1115-1123.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Antithrombin (Recombinant). Hospital Pharmacy, 2009, 44, 785-793.	0.4	3
128	Fospropofol Disodium. Hospital Pharmacy, 2009, 44, 242-250.	0.4	3
129	Granisetron Transdermal System. Hospital Pharmacy, 2009, 44, 332-339.	0.4	1
130	Tenofovir Disoproxil Fumarate Tablets. Hospital Pharmacy, 2009, 44, 165-178.	0.4	0
131	Certolizumab pegol for the treatment of Crohn's disease. Expert Review of Clinical Immunology, 2009, 5, 683-691.	1.3	4
132	Rufinamide. Hospital Pharmacy, 2009, 44, 412-422.	0.4	2
133	Golimumab. Hospital Pharmacy, 2009, 44, 894-907.	0.4	2
134	Regadenoson Injection. Hospital Pharmacy, 2009, 44, 57-68.	0.4	1
135	New Dosage Forms and Indications Approved by the FDA Agents Pending FDA Approval Significant Labeling Changes or "Dear Health Care Professional" Letters Related to Safety. Hospital Pharmacy, 2009, 44, 423-427.	0.4	0
136	Febuxostat. Hospital Pharmacy, 2009, 44, 688-699.	0.4	0
137	Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction. Reviews in Gastroenterological Disorders, 2009, 9, E84-93.	0.6	5
138	Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole. Reviews in Gastroenterological Disorders, 2009, 9, E111-8.	0.6	2
139	Sumatriptan Succinate/Naproxen Sodium. Hospital Pharmacy, 2008, 43, 650-660.	0.4	0
140	Sapropterin Dihydrochloride Tablets. Hospital Pharmacy, 2008, 43, 307-314.	0.4	0
141	New Drugs Approved by the FDA Agents Pending FDA Approval Supplemental Applications Filed by Manufacturer Significant Labeling Changes. Hospital Pharmacy, 2008, 43, 410-418.	0.4	0
142	Data Supporting the Use of Prescription Medications for Off-Label Indications. Hospital Pharmacy, 2008, 43, 956-957.	0.4	1
143	Clevidipine Butyrate Injectible Emulsion. Hospital Pharmacy, 2008, 43, 903-912.	0.4	9
144	Certolizumab Pegol. Hospital Pharmacy, 2008, 43, 998-1010.	0.4	0

#	ARTICLE	IF	CITATIONS
145	Hydroxyethyl Starch 130/0.4. Hospital Pharmacy, 2008, 43, 396-408.	0.4	3
146	Thrombin, Topical (Recombinant). Hospital Pharmacy, 2008, 43, 577-585.	0.4	10
147	Human Patient Simulation: Is this Included in your List of Job or Residency Interview Questions for New Graduates?. Hospital Pharmacy, 2008, 43, 693-694.	0.4	0
148	Alvimopan. Hospital Pharmacy, 2008, 43, 819-829.	0.4	0
149	New Drugs Approved by the FDA; Agents Pending FDA Approval; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes. Hospital Pharmacy, 2008, 43, 317-322.	0.4	0
150	Methylnaltrexone Bromide, Subcutaneous. Hospital Pharmacy, 2008, 43, 734-743.	0.4	1
151	Raltegravir Potassium. Hospital Pharmacy, 2008, 43, 127-135.	0.4	0
152	Doripenem for Injection. Hospital Pharmacy, 2008, 43, 210-221.	0.4	3
153	Etravirine. Hospital Pharmacy, 2008, 43, 498-510.	0.4	2
154	Dexrazoxane. Hospital Pharmacy, 2008, 43, 43-49.	0.4	0
155	Systematic Reviews and Meta-Analyses: "Caveat Emptor"™. Hospital Pharmacy, 2008, 43, 80-80.	0.4	0
156	Pylera plus omeprazole: quadruple treatment for Helicobacter pylori. Reviews in Gastroenterological Disorders, 2008, 8, 33-41.	0.6	3
157	Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease. Reviews in Gastroenterological Disorders, 2008, 8, 240-53.	0.6	2
158	Posaconazole Oral Suspension. Hospital Pharmacy, 2007, 42, 57-72.	0.4	1
159	Arformoterol Tartrate. Hospital Pharmacy, 2007, 42, 447-454.	0.4	1
160	Inhaled dry powder insulin for the treatment of diabetes mellitus. Clinical Therapeutics, 2007, 29, 795-813.	1.1	18
161	Mesalamine. Hospital Pharmacy, 2007, 42, 543-552.	0.4	1
162	New Drugs Approved by the FDA: Agents Pending FDA Approval Supplemental Applications Filed by Manufacturer Significant Labeling Changes. Hospital Pharmacy, 2007, 42, 356-358.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Aliskiren. Hospital Pharmacy, 2007, 42, 737-750.	0.4	3
164	Fentanyl Effervescent Buccal Tablet. Hospital Pharmacy, 2007, 42, 230-239.	0.4	0
165	Sitagliptin Phosphate. Hospital Pharmacy, 2007, 42, 133-140.	0.4	0
166	New Drugs Approved by the FDA Agents Pending FDA Approval Supplemental Applications Filed by Manufacturer Significant Labeling Changes. Hospital Pharmacy, 2007, 42, 1156-1162.	0.4	2
167	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes. Hospital Pharmacy, 2007, 42, 141-144.	0.4	0
168	Ambrisentan. Hospital Pharmacy, 2007, 42, 1145-1154.	0.4	3
169	Drug Safety Information. Hospital Pharmacy, 2007, 42, 978-980.	0.4	0
170	New Drugs Approved by the FDA; Agents Pending FDA Approval; Supplemental Applications Filed by Manufacturer; Significant Labeling Changes Baker. Hospital Pharmacy, 2007, 42, 1061-1070.	0.4	0
171	Editorial - Influenza Vaccinations and Back-to-School Shopping. Hospital Pharmacy, 2007, 42, 674-674.	0.4	0
172	Telbivudine. Hospital Pharmacy, 2007, 42, 345-355.	0.4	0
173	Retapamulin 1% Ointment. Hospital Pharmacy, 2007, 42, 846-855.	0.4	1
174	Rotigotine Transdermal System. Hospital Pharmacy, 2007, 42, 939-950.	0.4	1
175	MedWatch's Drug Safety Alert System. Hospital Pharmacy, 2007, 42, 394-395.	0.4	0
176	Maraviroc. Hospital Pharmacy, 2007, 42, 1046-1057.	0.4	0
177	Natalizumab: overview of its pharmacology and safety. Reviews in Gastroenterological Disorders, 2007, 7, 38-46.	0.6	15
178	Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus. Clinical Therapeutics, 2006, 28, 652-665.	1.1	82
179	Anidulafungin. Hospital Pharmacy, 2006, 41, 669-681.	0.4	1
180	Ramelteon. Hospital Pharmacy, 2006, 41, 59-69.	0.4	2

#	ARTICLE	IF	CITATIONS
181	Ibandronate Intravenous. Hospital Pharmacy, 2006, 41, 868-879.	0.4	2
182	Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine. Hospital Pharmacy, 2006, 41, 1185-1195.	0.4	1
183	Over-the-Counter Orlistat. Hospital Pharmacy, 2006, 41, 497-498.	0.4	0
184	Lidocaine/Tetracaine Patch. Hospital Pharmacy, 2006, 41, 265-273.	0.4	11
185	The Implementation of Medicare Part D. Hospital Pharmacy, 2006, 41, 220-220.	0.4	0
186	Insulin Human (rDNA Origin) Inhalation Powder. Hospital Pharmacy, 2006, 41, 560-573.	0.4	0
187	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes. Hospital Pharmacy, 2006, 41, 683-688.	0.4	0
188	Campaign to Eliminate Use of Error-Prone Abbreviations. Hospital Pharmacy, 2006, 41, 809-810.	0.4	0
189	Formulary Drug Reviews - Ibuprofen Lysine Injection. Hospital Pharmacy, 2006, 41, 970-978.	0.4	0
190	Intravenous proton pump inhibitors. Reviews in Gastroenterological Disorders, 2006, 6, 22-34.	0.6	5
191	MMX mesalamine. Reviews in Gastroenterological Disorders, 2006, 6, 146-52.	0.6	9
192	Pentetate Calcium Trisodium (Ca-DTPA) and Pentetate Zinc Trisodium (Zn-DTPA). Hospital Pharmacy, 2005, 40, 65-71.	0.4	0
193	Entecavir. Hospital Pharmacy, 2005, 40, 798-811.	0.4	0
194	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes. Hospital Pharmacy, 2005, 40, 614-625.	0.4	0
195	Palifermin. Hospital Pharmacy, 2005, 40, 515-526.	0.4	0
196	Lanthanum Carbonate. Hospital Pharmacy, 2005, 40, 250-261.	0.4	0
197	Tamiflu: Drug Hoarding vs Public Stockpiling. Hospital Pharmacy, 2005, 40, 1027-1027.	0.4	0
198	Metered-Dose Inhalers and the Ozone Layer. Hospital Pharmacy, 2005, 40, 642-642.	0.4	0

#	ARTICLE	IF	CITATIONS
199	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes Related to Safety. Hospital Pharmacy, 2005, 40, 170-183.	0.4	0
200	Use of Color on Pharmaceutical Labels and Packaging. Hospital Pharmacy, 2005, 40, 296-297.	0.4	4
201	Rationale for using serotonergic agents to treat irritable bowel syndrome. American Journal of Health-System Pharmacy, 2005, 62, 700-711.	0.5	52
202	Pramlintide Acetate. Hospital Pharmacy, 2005, 40, 599-613.	0.4	0
203	Exenatide Injection. Hospital Pharmacy, 2005, 40, 994-1003.	0.4	0
204	Insulin Detemir. Hospital Pharmacy, 2005, 40, 1062-1074.	0.4	2
205	Medication Safety and Radio Frequency Identification Technology. Hospital Pharmacy, 2005, 40, 10-10.	0.4	1
206	Eszopiclone. Hospital Pharmacy, 2005, 40, 430-442.	0.4	0
207	Micafungin Sodium. Hospital Pharmacy, 2005, 40, 693-704.	0.4	0
208	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes. Hospital Pharmacy, 2005, 40, 813-821.	0.4	0
209	Hydromorphone Hydrochloride Extended-Release Capsules (C-II). Hospital Pharmacy, 2005, 40, 156-164.	0.4	0
210	A Comparison of Educational Methods to Improve NSAID Knowledge and Use of a Medication List in an Elderly Population. Home Health Care Management and Practice, 2005, 17, 403-410.	0.4	2
211	Phosphodiesterase 5 Inhibitors for Erectile Dysfunction. Annals of Pharmacotherapy, 2005, 39, 1286-1295.	0.9	69
212	Rifaximin: a nonabsorbed oral antibiotic. Reviews in Gastroenterological Disorders, 2005, 5, 19-30.	0.6	22
213	Adefovir dipivoxil: focus on its use in the treatment of chronic hepatitis B. Reviews in Gastroenterological Disorders, 2005, 5, 89-100.	0.6	3
214	Safety of balsalazide therapy in the treatment of inflammatory bowel disease. Reviews in Gastroenterological Disorders, 2005, 5, 135-41.	0.6	2
215	Ezetimibe/Simvastatin. Hospital Pharmacy, 2004, 39, 1076-1088.	0.4	0
216	Rosuvastatin Calcium. Hospital Pharmacy, 2004, 39, 52-68.	0.4	0

#	ARTICLE	IF	CITATIONS
217	Acamprosate Calcium Delayed-Release Tablets. Hospital Pharmacy, 2004, 39, 1177-1188.	0.4	0
218	Memantine. Hospital Pharmacy, 2004, 39, 254-263.	0.4	0
219	Risperidone Long-Acting Injection. Hospital Pharmacy, 2004, 39, 353-363.	0.4	2
220	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Significant Labeling Changes Related to Safety. Hospital Pharmacy, 2004, 39, 880-894.	0.4	0
221	New Drugs Approved by the FDA: New Dosage Forms and Indications: Agents Pending FDA Approval: Significant Labeling Changes Related to Safety. Hospital Pharmacy, 2004, 39, 1089-1100.	0.4	0
222	Cinacalcet Hydrochloride. Hospital Pharmacy, 2004, 39, 666-680.	0.4	0
223	Peer Review: Personal Continuous Quality Improvement. Hospital Pharmacy, 2004, 39, 8-8.	0.4	0
224	Olanzapine for Injection (Intramuscular). Hospital Pharmacy, 2004, 39, 776-785.	0.4	0
225	Improved Access to Information from Clinical Trials with Negative Results. Hospital Pharmacy, 2004, 39, 930-930.	0.4	1
226	Intravenous N-Acetylcysteine. Hospital Pharmacy, 2004, 39, 564-570.	0.4	0
227	Parachutes and Evidence-Based Medicine. Hospital Pharmacy, 2004, 39, 618-619.	0.4	2
228	Botulism Immune Globulin Intravenous. Hospital Pharmacy, 2004, 39, 470-477.	0.4	0
229	Tinidazole. Hospital Pharmacy, 2004, 39, 976-987.	0.4	0
230	Morphine Sulfate Extended-Release Liposome Injection. Hospital Pharmacy, 2004, 39, 871-879.	0.4	1
231	Therapeutic equivalence of mesalamine products. Reviews in Gastroenterological Disorders, 2004, 4, 25-8.	0.6	1
232	The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Reviews in Gastroenterological Disorders, 2004, 4, 86-91.	0.6	18
233	Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Reviews in Gastroenterological Disorders, 2004, 4, 196-210.	0.6	24
234	Emtricitabine. Hospital Pharmacy, 2003, 38, 1151-1160.	0.4	0

#	ARTICLE	IF	CITATIONS
235	Teriparatide. Hospital Pharmacy, 2003, 38, 463-473.	0.4	0
236	Icodextrin Peritoneal Dialysis Solution. Hospital Pharmacy, 2003, 38, 669-678.	0.4	1
237	Reducing Medication Errors with Prescription Bar Coding. Hospital Pharmacy, 2003, 38, 10-11.	0.4	0
238	Medication Counterfeiting: The Next Form of Terrorism or Just Greed?. Hospital Pharmacy, 2003, 38, 194-195.	0.4	0
239	Pharmacogenomics and Drug Product Labeling. Hospital Pharmacy, 2003, 38, 524-524.	0.4	0
240	Summit Meeting on Pharmaceutical Bar Coding. Hospital Pharmacy, 2003, 38, 817-817.	0.4	0
241	Influenza Virus Vaccine, Live, Intranasal. Hospital Pharmacy, 2003, 38, 947-957.	0.4	0
242	Gemifloxacin Mesylate. Hospital Pharmacy, 2003, 38, 851-861.	0.4	0
243	Rasburicase. Hospital Pharmacy, 2003, 38, 50-57.	0.4	0
244	Aprepitant. Hospital Pharmacy, 2003, 38, 763-774.	0.4	1
245	Ezetimibe. Hospital Pharmacy, 2003, 38, 357-366.	0.4	1
246	Adefovir Dipivoxil. Hospital Pharmacy, 2003, 38, 144-154.	0.4	1
247	Oxaliplatin: a new drug for the treatment of metastatic carcinoma of the colon or rectum. Reviews in Gastroenterological Disorders, 2003, 3, 31-8.	0.6	14
248	Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Reviews in Gastroenterological Disorders, 2003, 3, 93-109.	0.6	19
249	Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Reviews in Gastroenterological Disorders, 2003, 3, 150-7.	0.6	10
250	Insulin Glargine: A New Basal Insulin. Annals of Pharmacotherapy, 2002, 36, 1019-1027.	0.9	50
251	Treprostinil Sodium Injection. Hospital Pharmacy, 2002, 37, 1196-1204.	0.4	0
252	Frovatriptan Succinate. Hospital Pharmacy, 2002, 37, 391-401.	0.4	0

#	ARTICLE	IF	CITATIONS
253	The Pharmacy Preceptor: A Critical Link in Pharmacy Education. Hospital Pharmacy, 2002, 37, 576-576.	0.4	0
254	Interferon Beta-1a. Hospital Pharmacy, 2002, 37, 957-966.	0.4	0
255	Ziprasidone Mesylate for Injection. Hospital Pharmacy, 2002, 37, 1307-1317.	0.4	0
256	Drotrecogin Alfa. Hospital Pharmacy, 2002, 37, 511-520.	0.4	0
257	Cefditoren Pivoxil. Hospital Pharmacy, 2002, 37, 274-284.	0.4	0
258	Fondaparinux Sodium. Hospital Pharmacy, 2002, 37, 737-747.	0.4	0
259	HIPAA Privacy Rules. Hospital Pharmacy, 2002, 37, 908-910.	0.4	1
260	Pegfilgrastim. Hospital Pharmacy, 2002, 37, 840-848.	0.4	0
261	Sound-Alike and Look-Alike Drug Errors. Hospital Pharmacy, 2002, 37, 225-225.	0.4	0
262	Imatinib mesylate. Reviews in Gastroenterological Disorders, 2002, 2, 75-86.	0.6	3
263	Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Reviews in Gastroenterological Disorders, 2002, 2, 20-33.	0.6	9
264	Esomeprazole: update and clinical review. Reviews in Gastroenterological Disorders, 2002, 2, 189-99.	0.6	0
265	Insulin glargine. Clinical Therapeutics, 2001, 23, 1938-1957.	1.1	43
266	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval. Hospital Pharmacy, 2001, 36, 319-325.	0.4	0
267	Almotriptan Malate. Hospital Pharmacy, 2001, 36, 1066-1078.	0.4	0
268	Providing New Safety Information to Prescribers. Hospital Pharmacy, 2001, 36, 242-242.	0.4	0
269	Pantoprazole IV. Hospital Pharmacy, 2001, 36, 846-855.	0.4	1
270	New Drugs Approved by the FDA/New Dosage Forms and Indications/Agents Pending FDA Approval/Labeling Changes Related to Safety. Hospital Pharmacy, 2001, 36, 1096-1111.	0.4	0

#	ARTICLE	IF	CITATIONS
271	Do "Dear Health Care Professional" Letters Make a Difference?. Hospital Pharmacy, 2001, 36, 928-928.	0.4	0
272	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval. Hospital Pharmacy, 2001, 36, 664-676.	0.4	0
273	Sodium Phosphate Monobasic Monohydrate, USP and Sodium Phosphate Anhydrous, USP. Hospital Pharmacy, 2001, 36, 306-312.	0.4	0
274	Meperidine: A Drug past its Prime. Hospital Pharmacy, 2001, 36, 1131-1132.	0.4	2
275	Formoterol Fumarate Inhalation Powder. Hospital Pharmacy, 2001, 36, 753-767.	0.4	1
276	Nateglinide Therapy for Type 2 Diabetes Mellitus. Annals of Pharmacotherapy, 2001, 35, 1426-1434.	0.9	25
277	Lopinavir/Ritonavir. Hospital Pharmacy, 2000, 35, 83-92.	0.4	0
278	Meloxicam. Hospital Pharmacy, 2000, 35, 852-865.	0.4	2
279	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Major Labeling Changes. Hospital Pharmacy, 2000, 35, 761-774.	0.4	0
280	Dofetilide. Hospital Pharmacy, 2000, 35, 526-535.	0.4	0
281	Alosetron. Hospital Pharmacy, 2000, 35, 631-638.	0.4	0
282	Pneumococcal 7-Valent Conjugate Vaccine. Hospital Pharmacy, 2000, 35, 750-760.	0.4	4
283	New Drugs Approved by the FDA; New Dosage Forms and Indications; Agents Pending FDA Approval; Major Labeling Changes. Hospital Pharmacy, 2000, 35, 871-878.	0.4	0
284	Zaleplon. Hospital Pharmacy, 2000, 35, 77-86.	0.4	1
285	Tenecteplase. Hospital Pharmacy, 2000, 35, 1090-1098.	0.4	0
286	Methylphenidate Extended-Release Tablets. Hospital Pharmacy, 2000, 35, 1319-1327.	0.4	0
287	Insulin Aspart. Hospital Pharmacy, 2000, 35, 1221-1229.	0.4	0
288	Miglitol: Assessment of its Role in the Treatment of Patients with Diabetes Mellitus. Annals of Pharmacotherapy, 2000, 34, 1291-1301.	0.9	89

#	ARTICLE	IF	CITATIONS
289	Risedronate Sodium and Tirofiban Hydrochloride. Hospital Pharmacy, 1999, 34, 207-231.	0.4	0
290	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval Market Withdrawals Major Labeling Changes. Hospital Pharmacy, 1999, 34, 364-374.	0.4	0
291	Paricalcitol Injection and Ribavirin/Interferon Alfa-2b. Hospital Pharmacy, 1999, 34, 303-338.	0.4	1
292	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval Market Withdrawals Major Labeling Changes. Hospital Pharmacy, 1999, 34, 492-501.	0.4	0
293	New Drugs Approved by the FDA New Dosage Forms and Indications Agents Pending FDA Approval Market Withdrawals Major Labeling Changes. Hospital Pharmacy, 1999, 34, 579-590.	0.4	0
294	Cilostazol. Hospital Pharmacy, 1999, 34, 859-871.	0.4	0
295	Sildenafil (Viagra) for the Treatment of Erectile Dysfunction in Men With Diabetes. The Diabetes Educator, 1999, 25, 79-89.	2.6	6
296	Direct Measurement of Unfractionated Heparin Using a Biochemical Assay. Clinical and Applied Thrombosis/Hemostasis, 1999, 5, 267-276.	0.7	1
297	Selected Topics in Drug Information Access and Practice: An Update. Annals of Pharmacotherapy, 1994, 28, 1389-1394.	0.9	7
298	Vitamin and Mineral Supplementation in Patients with Diabetes Mellitus. The Diabetes Educator, 1992, 18, 420-427.	2.6	22
299	Therapeutic Advances in the Prevention of Hepatitis B: Yeast-Derived Recombinant Hepatitis B Vaccines. DICP: the Annals of Pharmacotherapy, 1991, 25, 617-627.	0.2	8
300	Pharmacy Update. The Diabetes Educator, 1990, 16, 313-316.	2.6	1
301	Piroxicam-Furosemide Drug Interaction. Drug Intelligence & Clinical Pharmacy, 1988, 22, 505-506.	0.4	1
302	Pentoxifylline: A New Agent for Intermittent Claudication. Drug Intelligence & Clinical Pharmacy, 1985, 19, 345-348.	0.4	18
303	The Second Generation Sulfonylureas: Glipizide and Glyburide. The Diabetes Educator, 1985, 11, 29-36.	2.6	1
304	Trental: A New Medication for Diabetic Peripheral Vascular Disorders. The Diabetes Educator, 1984, 10, 66-66.	2.6	0
305	Meloxicam Intravenous Injection. Hospital Pharmacy, 0, , 001857872096543.	0.4	0
306	Oliceridine. Hospital Pharmacy, 0, , 001857872098713.	0.4	0

#	ARTICLE	IF	CITATIONS
307	Fostemsavir. Hospital Pharmacy, 0, , 001857872098543.	0.4	1
308	Vericiguat. Hospital Pharmacy, 0, , 001857872110163.	0.4	0
309	Formulary Drug Review: Cabotegravir. Hospital Pharmacy, 0, , 001857872110295.	0.4	0
310	Dasiglucagon. Hospital Pharmacy, 0, , 001857872110468.	0.4	1
311	Formulary Drug Review: Odevixibat. Hospital Pharmacy, 0, , 001857872110690.	0.4	0
312	Formulary Drug Review: Belumosudil. Hospital Pharmacy, 0, , 001857872110613.	0.4	0
313	Avacopan. Hospital Pharmacy, 0, , 001857872210871.	0.4	0